Lymphangiomyomatosis With Chylous Effusions

Autor: Beall Ac, Greenberg Sd, Sheth Ra, Jenkins De

Publikováno v: Southern Medical Journal. 77:1032-1035

We report two cases of lymphangiomyomatosis with pleural and peritoneal chylous effusions, one without pulmonary involvement. The first patient died after seven years. The second received external irradiation to control the chylous ascites and remain

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c531cc63a5cc8361b4e8abb6b21411
https://doi.org/10.1097/00007611-198408000-00024

Caveat Lector: The Importance of Becoming a Discerning Guidelines Reader.

Autor: Wilkins LR; Section of Vascular and Interventional Radiology, Department of Radiology and Medical Imaging, University of Virginia School of Medicine, Charlottesville, Virginia. Electronic address: wilkins@virginia.edu., Sheth RA; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas., Tabori NE; Section of Interventional Radiology, Department of Radiology, MedStar Washington Hospital Center, Washington, DC., Tam AL; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2024 Oct 09. Date of Electronic Publication: 2024 Oct 09.

Safety and Efficacy of Percutaneous Cryoablation for Recurrent or Metastatic Soft-Tissue Sarcoma in Adult Patients.

Autor: Pal K; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Awad A; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Yevich S; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Kuban JD; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Tam AL; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Huang SY; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Odisio BC; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Gupta S; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Habibollahi P; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009., Bishop AJ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Conley AP; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Somaiah N; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Araujo D; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Zarzour MA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Ravin R; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Roland CL; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Keung EZ; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Sheth RA; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1471, Houston, TX 77030-4009.

Publikováno v: AJR. American journal of roentgenology [AJR Am J Roentgenol] 2024 Oct; Vol. 223 (4), pp. e2431490. Date of Electronic Publication: 2024 Jul 31.

A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.

Autor: Campbell MT; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Shah AY; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Msaouel P; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Tannir NM; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Siefker-Radtke AO; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Navai N; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Dinney CPN; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Rao P; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Guo CC; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Sheth RA; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas., Venkatesan AM; Division of Diagnostic Imaging, Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas., Tidwell RS; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas., Yadav SS; Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas., Gu A; Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas., Chen H; Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas.; James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas., Macaluso M; Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas.; James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas., Duan F; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Basu S; Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas.; James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas., Jindal S; Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas.; James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas., Sharma P; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.; Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas.; James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas.; Department of Immunology, University of MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Sep 01; Vol. 4 (9), pp. 2444-2453.

Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis.

Autor: Siddiqui BA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Palaskas NL; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Basu S; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dai Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., He Z; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yadav SS; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Allison JP; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sheth RA; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tummala S; Department of Neurology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Buja M; Department of Pathology, McGovern Medical School at UTHealth Houston, Houston, Texas., Bhattacharjee MB; Department of Pathology, McGovern Medical School at UTHealth Houston, Houston, Texas., Iliescu C; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rawther-Karedath A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Deswal A; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2024 Aug 01; Vol. 12 (8), pp. 964-987.